Roctavian (valoctocogene roxaparvovec-rvox) — HCPCS J3399

Hemophilia A therapy class — J3399 (Roctavian gene therapy) vs Hemlibra vs FVIII replacement CMS HCPCS verified May 2026

Three completely different treatment paradigms for hemophilia A. Don't confuse them at the claim layer.

Hemophilia A (congenital factor VIII deficiency, the more common hemophilia — ~80% of all hemophilia) is treated by three paradigms: (1) FVIII replacement therapy — standard-half-life or extended-half-life recombinant or plasma-derived factor VIII given on demand or as prophylaxis multiple times per week indefinitely (Advate, Adynovate, Eloctate, Esperoct, Jivi, Kovaltry, Kogenate FS, NovoEight, Nuwiq, Recombinate, Xyntha, Altuviiio, and plasma-derived FVIII concentrates), (2) Hemlibra (emicizumab) — subcutaneous bispecific FVIIIa mimetic prophylaxis given weekly to monthly, used in most severe hemophilia A patients today (with or without inhibitors), and (3) Roctavian gene therapy — one-time IV AAV5 vector delivering an hFVIII-SQ transgene to hepatocytes for sustained endogenous FVIII production. They have entirely different mechanisms, schedules, and billing pathways.

Dosing & unit math FDA label verified May 2026

From the FDA-approved Roctavian prescribing information (BLA 125720). Unit-of-billing is the per-therapeutic-dose event, not vials or vg; the underlying physical dose is weight-based vector genome copies.

Approved indication

• Severe hemophilia A (congenital factor VIII deficiency, FVIII activity ≤ 1 IU/dL) in adult patients (≥18 years) who:
  • are anti-AAV5 antibody negative by validated assay, AND
  • have NO current OR historical FVIII inhibitors (negative Bethesda assay AND no documented inhibitor history), AND
  • have negative active hepatitis B / C / HIV serology.
• Most candidates are on FVIII prophylaxis or Hemlibra prophylaxis at the time of evaluation; documentation must include the most recent FVIII activity assay result and full lifetime FVIII inhibitor history.

Weight-based dosing

Worked example — 70 kg adult on routine HTC severe hemophilia A workflow

Dose modifications

Per FDA label, Roctavian dosing is fixed at 6 × 10¹³ vg/kg. There is no dose reduction pathway because the therapy is one-time and the AAV5 vector is sized to deliver therapeutic hFVIII-SQ transgene copies to hepatocytes. If pre-infusion LFTs, hepatitis serology, FVIII activity, or FVIII inhibitor status are out of range, the infusion is held rather than dose-reduced; the patient continues FVIII prophylaxis or Hemlibra while eligibility is re-established.

Anti-AAV5 antibody + FVIII inhibitor dual pre-treatment gate

Before infusion, anti-AAV5 antibody status must be negative by validated assay (GENEr8-1 pivotal trial exclusion criterion). Testing is coordinated through BioMarin patient support. Approximately 30% of adult hemophilia A patients screened have detectable anti-AAV5 antibodies (higher seroprevalence than for AAV9; comparable to or slightly higher than the AAV5 seroprevalence in adult hemophilia B). Patients with detectable anti-AAV5 antibodies are not eligible for Roctavian and remain on FVIII prophylaxis or Hemlibra. Additionally, the FVIII inhibitor gate is stricter than Hemgenix's: Roctavian requires NO current AND NO historical FVIII inhibitors (review the full lifetime treatment record, not just current Bethesda titer). Any documented prior FVIII inhibitor — even one that resolved — is an exclusion.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Roctavian is a therapeutic IV infusion (not chemo, not radiopharm, not a factor replacement push). Use therapeutic IV admin codes; expect to bill 96366 add-on hours given the 2–3 hour duration.

Modifiers CMS verified May 2026

JZ / JW — generally N/A for single-dose patient-specific gene therapy

Roctavian kits are patient-specific, lot-traceable, and built to deliver the exact weight-based dose. There is no physical "vial waste" in the conventional J-code sense — the entire shipped product is intended for administration to that named patient. JZ may be reported on J3399 to attest "no discarded amount from a single-dose container," consistent with CMS's July 2023 single-dose container policy, but practice varies by MAC and the per-therapeutic-dose / NOC unit definition makes JZ/JW reporting largely moot. Confirm with your MAC.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (consent, extended hematology counseling, baseline bleed assessment, lifetime inhibitor history review, review of 6-month weekly LFT monitoring plan, FVIII / Hemlibra prophylaxis bridging discussion).

340B modifiers (JG, TB)

Most Roctavian is dispensed under the specialty product / specialty distribution pathway rather than via 340B, but a small number of HTC-affiliated 340B-covered entities may administer 340B-acquired Roctavian. Confirm with your 340B compliance team and your MAC's modifier guidance. Outcomes-based contracts can complicate 340B reporting because the manufacturer rebate flow interacts with 340B pricing assumptions.

Contract-specific modifiers

Some commercial payers add a contract-specific modifier or claim attachment requirement to flag claims under an outcomes-based agreement (so the claim can be linked to the manufacturer's milestone-tracking dataset). Follow the payer's outcomes-based contract operational guide; BioMarin patient support coordinates this end-to-end.

NOC-code documentation modifiers

Because J3399 is a not-otherwise-classified code, most MACs require detailed claim attachments (drug name, NDC, dose administered in vg, invoice copy, manufacturer's product information). Some payers add modifier KX (specific required documentation on file) to attest the attachment is present. Verify the payer's NOC-claim documentation requirements before submission — this is the dominant reason for first-pass rejection of J3399 claims (often a documentation completeness denial rather than a clinical denial).

ICD-10-CM by indication FY2026 verified May 2026

Roctavian is indicated for adults with severe hemophilia A (congenital FVIII deficiency). Use D66 plus supporting codes documenting bleeding history, FVIII prophylaxis or Hemlibra history, and inhibitor-naive status.

Site of care & place of service Verified May 2026

Roctavian is administered exclusively in certified hemophilia treatment centers (HTCs) — almost always a federally-funded HTC (one of ~140 in the US National HTC Network) with a multi-disciplinary hemophilia / bleeding-disorders program. The administration is typically performed in a hospital outpatient infusion suite under extended observation (the more common pattern given the 2–3 hour infusion plus observation), or as a planned short admission at HTCs that prefer inpatient routing. Office-based (POS 11), ambulatory infusion center (POS 49), and home infusion administration is not appropriate given the high-cost product, infusion-reaction risk, and intensive post-infusion hepatic monitoring requirements (weekly × 6 months).

Claim form field mapping BioMarin 2026

Roctavian claims are typically submitted on UB-04 (837I) by the certified HTC. Because J3399 is a NOC code, claim attachments are critical.

Payer policy snapshot Reviewed May 2026

Universal PA. Anti-AAV5 antibody negative, severe hemophilia A (D66) with FVIII activity ≤ 1 IU/dL, age ≥18, NO current or historical FVIII inhibitors, hepatitis B/C/HIV serology negative, documented prior FVIII prophylaxis or Hemlibra history, and HTC certification are the universal documentation requirements.

Outcomes-based contracts — how they work for billers

BioMarin offers outcomes-based agreements (OBAs) with most major commercial payers and a growing list of state Medicaid programs. The typical structure: full WAC (~$2.9M) is paid at administration; if specified clinical milestones are not met over a multi-year horizon (commonly up to 5 years), a percentage of the WAC is refunded by the manufacturer to the payer. Milestones commonly include sustained FVIII activity threshold at multiple timepoints, annualized bleed rate (ABR) reduction, and elimination or reduction of FVIII product utilization. The provider's role: document FVIII activity (chromogenic and one-stage assays), bleed events, and FVIII product use at standardized intervals (3, 6, 12, 24, 36, 60 months post-infusion). BioMarin patient support coordinates this longitudinally. The rebate/refund flow is payer-side and does not affect the provider's payment at administration. Note: BioMarin's outcomes-based contracts often include durability-specific milestones (because FVIII activity in GENEr8-1 declined more rapidly than originally hoped); the manufacturer's risk-sharing on durability is more aggressive than Hemgenix's contract terms.

CMS Cell and Gene Therapy (CGT) Access Model

In January 2025, CMS launched the Cell and Gene Therapy Access Model, a voluntary multi-state Medicaid arrangement designed specifically for high-cost one-time gene therapies starting with sickle cell disease and expanding to hemophilia (both A and B). BioMarin and participating states negotiate uniform outcomes-based pricing through CMS as a facilitator. Verify your state's participation status and the impact on Roctavian Medicaid PA / claim workflow with your state Medicaid agency.

Step therapy & prior FVIII / Hemlibra therapy

Roctavian's FDA label requires severe hemophilia A (FVIII ≤ 1 IU/dL) and most candidates have been on prophylactic FVIII or Hemlibra before gene therapy. Many payers require documented trial / failure / contra- indication of Hemlibra prophylaxis as part of step therapy (because Hemlibra is well-tolerated, highly effective subcutaneous prophylaxis that already meets most patients' needs at lower lifetime cost). Document the FVIII / Hemlibra product history (manufacturer, dose, schedule, duration, ABR on prophylaxis) in the PA packet as direct evidence the label criterion is met AND as evidence for / against step therapy. Note: some payers also require explicit documentation of shared decision-making around Roctavian durability uncertainty.

Medicare / Medicaid reimbursement CMS Q2 2026 (NOC / invoice)

Roctavian is not currently priced via the standard quarterly ASP file (NOC / invoice pathway via J3399 or J3490 / J3590). For inpatient HOPD administration, the drug cost is packaged into the DRG with NTAP or outlier payment; for outpatient, OPPS pass-through (where active) historically applied.

Inpatient (Medicare / Medicaid)

When Roctavian is administered inpatient, the drug cost is bundled into the assigned DRG. Without a high-cost outlier or New Technology Add-On Payment (NTAP), this is not financially viable for the hospital. Most state Medicaid programs and Medicare contractors have negotiated supplemental rebate agreements (SRAs) and outcomes-based agreements specifically to handle Roctavian cash flow. The CMS Cell and Gene Therapy (CGT) Access Model provides a multi-state Medicaid framework expanding to hemophilia. Confirm the state Medicaid or Medicare contractor policy and the hospital's contract before scheduling the inpatient admission.

Outpatient (Medicare / Medicaid)

For outpatient HOPD administration, J3399 is billed with the appropriate revenue code (0636 or 0260 per payer), CPT 96365 + 96366 admin, and the required NOC documentation attachments (drug name, NDC, dose in vg, invoice). OPPS pass-through (if active) pays the drug at invoice + handling; if pass-through has expired or was never granted, packaging into the APC bundle is generally not viable and outpatient billing depends on payer-specific contractor pricing.

Coverage

No NCD specific to Roctavian or to AAV-based gene therapies generally. Coverage falls under MAC LCDs and payer-specific medical / pharmacy benefit policies. All MACs and major commercial payers cover Roctavian for FDA-approved on-label indications with documented severe hemophilia A (D66, FVIII ≤ 1 IU/dL), age ≥ 18, anti-AAV5 antibody negative, no current or historical FVIII inhibitors, hepatitis B/C/HIV serology negative, and the required pre-/post-infusion monitoring framework.

Code history

• J3399 — "Injection, adeno-associated virus vector, not otherwise specified, per therapeutic dose"; used at launch for Roctavian (and shared with Zolgensma at launch). Verify the current descriptor and any Roctavian-specific successor permanent J-code in each quarter's CMS HCPCS file.
• J3490 — unclassified drug code; used at launch for some payers; gradually replaced by J3399 as the gene therapy NOC for most payers.
• J3590 — unclassified biologic code; legacy alternative to J3490 for biologics; not appropriate once J3399 NOC pathway is established.
• C9399 — transitional pass-through C-code historically used at initial launch for some hospital outpatient claims; verify current CMS HCPCS file for current status.

Patient assistance — BioMarin Patient and Caregiver Resources BioMarin verified May 2026

• BioMarin Patient and Caregiver Resources (BPCR): BioMarin main patient support line 1-866-906-6100 — benefits investigation, prior authorization assistance, anti-AAV5 antibody testing logistics, certified HTC referral, travel and lodging support, FVIII / Hemlibra prophylaxis bridging coordination, post-infusion monitoring scheduling, outcomes-based contract operational support, durability counseling resources
• BioMarin patient assistance foundation: 501(c)(3) charitable foundation providing free product for uninsured / underinsured patients meeting income requirements; Roctavian access pathway is highly individualized given the WAC scale and narrow eligible population
• National Bleeding Disorders Foundation (NBDF, formerly NHF): bleeding.org — federally-funded HTC directory, MASAC clinical guidelines (Medical and Scientific Advisory Council) including the MASAC document on gene therapy in hemophilia A, peer/patient support, emergency financial assistance for travel and lodging
• Hemophilia Federation of America (HFA): hemophiliafed.org — patient advocacy, financial assistance programs, helping hands grants for emergency needs, mentorship and educational resources for adults considering gene therapy
• Foundations: PAN Foundation (rare/genetic disease funds where applicable), HealthWell Foundation, Patient Advocate Foundation — primarily supplemental for non-drug costs (travel, lodging, monitoring labs); verify open hemophilia / rare-disease funds quarterly
• Travel & lodging: BioMarin patient support coordinates with Healthcare Hospitality Network and Hope Lodge for patients traveling to certified Roctavian HTCs (regional access varies; far fewer certified Roctavian centers than Hemgenix centers given the lower commercial uptake)

Safety & FDA-label monitoring FDA label warnings & precautions

FDA-label warnings & precautions

• Hepatotoxicity / transaminase elevations: ALT elevations occurred in the majority of GENEr8-1 patients (substantially higher rate than Hemgenix's ~17%). Monitor ALT, AST, alkaline phosphatase, and total bilirubin at baseline (within 2 weeks pre-infusion) and weekly for at least 6 months post-infusion (longer than Hemgenix's 3-month minimum). If ALT rises above baseline or above ULN, initiate or extend reactive oral corticosteroid taper (commonly prednisone 60 mg/day with gradual taper, often > 12 weeks); coordinate with HTC hepatology consult.
• Infusion reactions: can occur during or immediately after the 2–3 hour infusion. Monitor vital signs during and for at least 3 hours post-infusion in HTC setting; have emergency response capability on standby. Pre-medication is not routinely required but may be considered per HTC protocol.
• Immune-mediated response / immunogenicity: patients seroconvert (develop anti-AAV5 antibodies) after Roctavian; re-dosing is not feasible. The label warns of immune-mediated response that can reduce FVIII expression and durability.
• Thromboembolic events: rare cases of thromboembolic events have been observed post-Roctavian as FVIII activity rises; monitor for clinical signs and educate patients.
• Theoretical risk of malignancy (AAV vector integration): the long-term safety monitoring plan includes annual or biannual follow-up for hepatic adverse events including hepatocellular carcinoma for up to 15 years; coordinate with HTC long-term registry.
• Active hepatitis B / C / HIV: patients with detectable hepatitis B or C viral load or uncontrolled HIV are excluded; the AAV5 vector is hepatotropic and uncontrolled hepatic infection increases risk. Document negative serology pre-infusion.
• Anti-AAV5 antibody seropositivity: patients with any detectable anti-AAV5 antibodies (total Ab or NAb) are excluded per GENEr8-1; the threshold is strict negativity (not a titer cutoff).
• FVIII inhibitor history (current or past): any documented prior FVIII inhibitor — even one that resolved — is an exclusion. Stricter than Hemgenix's contemporaneous-inhibitor-only criterion. Review the full lifetime treatment record.
• Embryo-fetal toxicity: Roctavian is not indicated in pregnant patients; reproductive counseling for adults of reproductive age.
• Durability counseling: GENEr8-1 long-term follow-up has shown FVIII activity declining more rapidly than originally projected; counsel patients realistically on durability and the possible need to return to FVIII / Hemlibra prophylaxis at some point post-infusion.

Outcomes-based milestone tracking

Beyond the FDA-label safety monitoring, the manufacturer's outcomes-based contract typically requires documentation of FVIII activity (chromogenic and one-stage assays), annualized bleed rate (ABR), and FVIII product utilization at 3, 6, 12, 24, 36, and 60 months post-infusion. BioMarin patient support coordinates this longitudinal data collection in cooperation with the certified HTC. Long-term safety registries (up to 15 years) capture malignancy, thromboembolic events, and durability data per FDA post-marketing commitments.

Common denials & how to fix them

Frequently asked questions

Is Roctavian a one-time treatment?

Yes. Roctavian is administered as a single one-time IV infusion. There is no repeat or maintenance dose. The hFVIII-SQ transgene delivered by the AAV5 vector is intended to drive endogenous factor VIII production in hepatocytes for years post-infusion (the GENEr8-1 trial demonstrated FVIII activity at multiple years of follow-up, though with steeper decline over time than originally projected). Re-dosing is not supported by the label and is generally not feasible because patients seroconvert (develop high-titer anti-AAV5 antibodies) after the first administration.

What is the HCPCS code for Roctavian?

Roctavian is billed under HCPCS J3399 — the gene therapy NOC (not otherwise classified) code, shared with other AAV-based gene therapies at launch. Some payers accept J3490 / J3590 unclassified codes; verify the current quarter's CMS HCPCS file and your MAC's instruction. Each Roctavian administration is billed as 1 unit per the per-therapeutic-dose definition. NOC claims require detailed documentation attachments (drug name, dose in vg, NDC, invoice).

How is Roctavian priced compared to Hemgenix and Zolgensma?

Roctavian's WAC at launch (~$2.9M) sits between Zolgensma's ~$2.1M and Hemgenix's ~$3.5M. All three are one-time AAV-based gene therapies. Hemgenix held the title of world's most expensive drug since 2022. Roctavian's lower WAC vs Hemgenix reflects market dynamics including Hemlibra's strong competition for severe hemophilia A and the narrower addressable population (AAV5 antibody-negative + lifetime-inhibitor- naive adults with severe disease).

What is the anti-AAV5 antibody threshold?

Per the GENEr8-1 pivotal trial exclusion criteria, patients with any detectable anti-AAV5 antibodies (total Ab or NAb) are excluded. This is a stricter binary criterion than Hemgenix's titer-based gate (< 1:678). The FDA label reflects this gate. Approximately 30% of hemophilia A patients screened have detectable anti-AAV5 antibodies. Missing or positive antibody documentation is the #1 cause of Roctavian PA denial. Coordinate testing through BioMarin patient support 4–6 weeks ahead of the planned infusion.

Why are FVIII inhibitors a contraindication?

Roctavian's label excludes patients with current OR historical FVIII inhibitors (any documented prior inhibitor, even one that resolved). This is stricter than Hemgenix (which only excludes current inhibitors). The rationale is that inhibitor formation against the AAV-expressed FVIII-SQ transgene product is a theoretical risk that is increased in patients who have previously developed FVIII inhibitors. For severe hemophilia A patients with inhibitor history, Hemlibra (J7170) or Alhemo (J7173) are the appropriate prophylactic options — both work in inhibitor patients.

How does outcomes-based contracting work for Roctavian billers?

BioMarin offers outcomes-based agreements (OBAs) to payers. Full WAC is paid at administration; if specified clinical milestones (sustained FVIII activity, ABR reduction, FVIII product use reduction) are not met over a 5-year horizon, a percentage of WAC is refunded by the manufacturer to the payer. BioMarin's OBAs often include explicit durability milestones (because GENEr8-1 follow-up has shown FVIII activity declining over time). The provider organization is not party to the rebate flow but documents FVIII activity (chromogenic and one-stage), bleeding events, and FVIII product use at 3, 6, 12, 24, 36, and 60 months post-infusion. BioMarin patient support coordinates this longitudinal data collection.

How is Roctavian administration paid for given the $2.9M price tag?

Through payer contracts and outcomes-based agreements, not patient out-of-pocket. Most adult patients are commercial-payer or Medicare-eligible; severe hemophilia A patients often qualify for Medicare under disability. State Medicaid programs increasingly access Roctavian through the CMS Cell and Gene Therapy Access Model (multi-state Medicaid framework launched 2025, expanding to hemophilia). Commercial payers use a combination of standard medical benefit + stop-loss reinsurance + outcomes-based contracts + benefit-pool carve-outs. Patient OOP exposure is typically capped at the plan's OOP maximum (varies by plan), not the WAC. BioMarin patient support and copay-assistance foundations help bridge any residual exposure.

Inpatient billing vs outpatient billing — which is right?

Both pathways are used, but HOPD extended observation (POS 22) is the more common framework for Roctavian given the 2–3 hour infusion plus observation. Some HTCs bill inpatient under a planned short admission (DRG with NTAP / outlier payment), especially when the contract favors inpatient or risk tolerance demands admission. The choice is driven by payer contract, hospital revenue cycle policy, and clinical risk tolerance. Confirm with the hospital's revenue cycle team and the payer before scheduling.

Is corticosteroid prophylaxis required?

Reactive / prophylactic taper is standard. Most HTCs initiate prednisone (commonly 60 mg/day taper) either prophylactically peri-infusion or reactively when ALT rises. The taper duration is often longer than Hemgenix's (> 12 weeks is common) because Roctavian's transaminase elevation rate is higher and more sustained. Document the corticosteroid plan in the PA packet and chart at every weekly monitoring visit.

What liver toxicity monitoring is required?

Per FDA label: ALT, AST, alkaline phosphatase, and total bilirubin at baseline (within 2 weeks pre-infusion) and weekly for at least 6 months post-infusion (substantially longer than Hemgenix's 3-month minimum). Concurrent FVIII activity assay at protocol-defined timepoints. Document the monitoring schedule in the PA packet and chart at every visit. Hepatitis B / C / HIV serology must be negative pre-infusion.

How do the National Bleeding Disorders Foundation and HFA support patients?

The National Bleeding Disorders Foundation (NBDF, bleeding.org; formerly NHF) and Hemophilia Federation of America (HFA, hemophiliafed.org) do not directly pay for Roctavian drug cost (that is the payer / Medicare / Medicaid / BioMarin path). They provide: federally-funded HTC directory, MASAC clinical guidelines (NBDF), helping hands financial assistance (HFA), peer/patient support, and emergency travel/lodging assistance. Refer adults considering gene therapy to NBDF and HFA early in the PA process.

Can a patient on Hemlibra switch to Roctavian?

Yes, but with careful timing. Hemlibra (emicizumab) has a long half-life (~28 days), and the FVIII activity assay required for Roctavian baseline can be confounded by Hemlibra-related assay interference. Coordinate with BioMarin patient support and the HTC to time the Hemlibra washout, the FVIII activity confirmation (must be ≤ 1 IU/dL by chromogenic assay), and the Roctavian scheduling. After Roctavian, Hemlibra is typically discontinued; some HTCs may use FVIII prophylaxis as a short safety bridge for 1–3 months. Document the bridging plan in the PA packet.

Roctavian vs Hemgenix vs Zolgensma — which is which?

Three different one-time AAV gene therapies for three different diseases. Roctavian (this page, J3399) is AAV5 gene therapy for adult severe hemophilia A (FVIII deficiency). Hemgenix (J1411) is AAV5 gene therapy for adult hemophilia B (FIX deficiency). Zolgensma (J3399) is AAV9 gene therapy for pediatric spinal muscular atrophy (SMA, SMN1 deficiency). They are not interchangeable — different diseases, different vectors, different age populations, different antibody thresholds.

Why has Roctavian uptake been so much lower than Hemgenix?

Several factors compress Roctavian's addressable market: adults only (≥ 18 yr); severe disease only (FVIII ≤ 1 IU/dL); AAV5 antibody-negative required (~30% seropositive); no current OR historical FVIII inhibitors (stricter than Hemgenix); Hemlibra (emicizumab) already provides excellent low-burden subcutaneous prophylaxis for most severe hemophilia A patients; and durability concerns from GENEr8-1 follow-up. Despite a larger underlying hemophilia A population, Roctavian's first 18–24 months of commercial uptake have been substantially lower than Hemgenix's. Counsel patients realistically on durability and the alternative of indefinite Hemlibra prophylaxis.

Source documents

1. FDA — ROCTAVIAN prescribing information (BLA 125720)
   FDA-approved label including warnings & precautions for hepatotoxicity, infusion reactions, immune-mediated response, thromboembolic events, theoretical malignancy risk, dosing, AAV5 antibody gate, FVIII inhibitor history exclusion, monitoring schedule
2. DailyMed — ROCTAVIAN (valoctocogene roxaparvovec-rvox)
   Current FDA label (setid 0dcf7185-8e1c-456a-9d4e-7cc316400118), NDC, package insert, patient counseling information. No boxed warning; prominent hepatotoxicity / transaminase elevation warning.
3. Roctavian.com — BioMarin patient site
   BioMarin Medical Information: 1-800-983-4587. Patient-facing information on eligibility, treatment process, and support resources. (BioMarin's product page at biomarin.com/products/roctavian/ has returned 404; use roctavian.com as the primary manufacturer reference.)
4. BioMarin Pharmaceutical Inc.
   Manufacturer corporate site; benefits investigation, PA assistance, anti-AAV5 antibody testing logistics, certified HTC directory, outcomes-based contract operations
5. CMS — Medicare Part B Drug ASP Pricing File
   Quarterly ASP file; J3399 (Roctavian NOC) historically priced via NOC / invoice rather than via ASP file (verify quarterly)
6. CMS — OPPS Addendum A / Addendum B
   Hospital outpatient status indicators; check J3399 status quarterly (pass-through vs packaged vs non-covered)
7. CMS — Cell and Gene Therapy (CGT) Access Model
   Multi-state Medicaid framework for high-cost gene therapies; launched January 2025, expanding to hemophilia A and B
8. National Bleeding Disorders Foundation (NBDF, formerly NHF)
   Federally-funded HTC directory, MASAC clinical guidelines (including MASAC document on gene therapy in hemophilia), peer/patient support
9. Hemophilia Federation of America (HFA)
   Patient advocacy, helping hands grants for emergency needs, mentorship for adults considering gene therapy
10. Ozelo et al., NEJM 2022 — GENEr8-1 pivotal trial of valoctocogene roxaparvovec (DOI 10.1056/NEJMoa2113708, PMID 35294811)
    Phase 3 single-arm trial (NEJM 386:1013-1025, March 17, 2022); basis for FDA approval; anti-AAV5 antibody-negative gate and FVIII inhibitor-naive criterion established here
11. Mahlangu et al., NEJM 2023 — Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A (DOI 10.1056/NEJMoa2211075, PMID 36812433)
    GENEr8-1 2-year follow-up (NEJM 388:694-705, February 23, 2023); documented FVIII activity decline trajectory that informs current durability counseling
12. Madan et al., J Thromb Haemost 2024 — Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A (DOI 10.1016/j.jtha.2024.04.001, PMID 38614387)
    GENEr8-1 3-year follow-up (JTH 22:1880-1893, July 2024); most recent published durability data referenced in payer policies and BioMarin outcomes-based contract structure
13. UnitedHealthcare — Roctavian Medical Drug Policy
14. Aetna CPB — Valoctocogene Roxaparvovec
15. FDA National Drug Code Directory
16. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — SME audit pass. Verified BLA 125720 / approval June 29, 2023 / no boxed warning via DailyMed (setid 0dcf7185-8e1c-456a-9d4e-7cc316400118). Added Mahlangu 2-year (NEJMoa2211075) and Madan 3-year (J Thromb Haemost 2024) GENEr8-1 durability follow-up citations — these are the primary sources behind the "FVIII activity declining more rapidly than originally projected" durability framing referenced throughout. Replaced broken BioMarin product-page link with roctavian.com (live, with BioMarin Medical Information 1-800-983-4587). Confirmed AAV5 gating is strict binary negativity (stricter than Hemgenix < 1:678) and FVIII inhibitor exclusion is lifetime (current AND historical), both of which are tighter than the corresponding Hemgenix gates.
• May 22, 2026 — Initial publication. ASP data: Q2 2026 (J3399 priced via NOC / invoice; not in standard ASP layer). Third gene therapy page in the CareCost catalog (after Zolgensma and Hemgenix). Manufacturer source: BioMarin 2026. Comparison vs Hemlibra (J7170) subcutaneous prophylaxis and FVIII replacement products. GENEr8-1 pivotal trial data referenced for anti-AAV5 antibody-negative gate, FVIII inhibitor-naive criterion, and hepatotoxicity / durability profile.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File and the OPPS Addendum B status indicator (where applicable; J3399 for Roctavian is commonly priced via NOC / invoice). Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list, dosing, anti-AAV5 antibody gate, FVIII inhibitor history exclusion, corticosteroid plan, and monitoring schedule are verified against the current FDA label revision. Outcomes-based contracting context is verified against BioMarin patient support operational guidance and the CMS Cell and Gene Therapy Access Model framework. We do not paraphrase from billing-software vendor blogs.